Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05814627




Registration number
NCT05814627
Ethics application status
Date submitted
4/04/2023
Date registered
18/04/2023
Date last updated
5/11/2024

Titles & IDs
Public title
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Scientific title
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)
Secondary ID [1] 0 0
2022-502578-18-00
Secondary ID [2] 0 0
M23-700
Universal Trial Number (UTN)
Trial acronym
SELECT- SWITCH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Upadacitinib
Treatment: Drugs - Adalimumab
Treatment: Drugs - Upadacitinib Matching Placebo
Treatment: Drugs - Adalimumab Matching Placebo

Experimental: Upadacitinib+ Adalimumab matching Placebo - Participants will receive upadacitinib once a day along with matching placebo for adalimumab at eow (every other week) in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.

Experimental: Adalimumab + Upadacitinib matching Placebo - Participants will receive adalimumab at eow (every other week) along with matching placebo for upadacitinib once a day in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.


Treatment: Drugs: Upadacitinib
Oral Tablets

Treatment: Drugs: Adalimumab
Subcutaneous Injection

Treatment: Drugs: Upadacitinib Matching Placebo
Oral Tablets

Treatment: Drugs: Adalimumab Matching Placebo
Subcutaneous Injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology 50 % (ACR50) Response
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) < 2.6
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Change from Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Change from Baseline in Participants Assessment of Pain
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Timepoint [5] 0 0
Week 12

Eligibility
Key inclusion criteria
* Diagnosis of Rheumatoid Arthritis (RA) for >= 3 months based on the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for RA.
* Treated for >= 3 consecutive months prior to screening with 1 tumor necrosis factor inhibitor (TNFi) (only 1 of originator or biosimilar certolizumab pegol, etanercept, golimumab or infliximab) for RA, but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity, irrespective of treatment duration. Up to 15% of participants who were intolerant to 1 TNFi will be allowed to enroll. Prior administration of different biosimilar versions for the same originator TNFi or switching between originator and biosimilar version of the same originator TNFi are acceptable. Cycling between biosimilars of different originator TNF inhibitors is not acceptable.
* On oral or parenteral methotrexate (MTX) therapy >= 3 consecutive months and on a stable prescription of 15 to 25 mg/week (or >= 10 mg/week in participants intolerant of MTX at doses >= 15 mg/week) for >= 4 weeks prior to the first dose of study drug. In addition, all participants should take a dietary supplement of folic acid or folinic acid throughout the study participation.

* For a Chinese, Japanese, Korean, or Taiwanese participant, a stable dose of MTX >= 7.5 mg/week is acceptable.
* Additional local requirements for MTX may apply.
* Meets both of the following disease activity criteria:

* >= 6 swollen joint (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at screening and baseline;
* High-sensitivity C-reactive protein (hsCRP) >= 3 mg/L (central lab, upper limit of normal [ULN] 2.87 mg/L) at screening.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA).
* Prior exposure to any janus kinase (JAK) inhibitor.
* Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab.
* Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/08/2026
Actual
Sample size
Target
480
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Montana
Country [18] 0 0
United States of America
State/province [18] 0 0
Nebraska
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New Mexico
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Argentina
State/province [30] 0 0
Ciudad Autonoma De Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Tucuman
Country [32] 0 0
Belgium
State/province [32] 0 0
Limburg
Country [33] 0 0
Belgium
State/province [33] 0 0
Oost-Vlaanderen
Country [34] 0 0
Belgium
State/province [34] 0 0
Brugge
Country [35] 0 0
Belgium
State/province [35] 0 0
Liege
Country [36] 0 0
Brazil
State/province [36] 0 0
Minas Gerais
Country [37] 0 0
Brazil
State/province [37] 0 0
Parana
Country [38] 0 0
Brazil
State/province [38] 0 0
Rio Grande Do Sul
Country [39] 0 0
Brazil
State/province [39] 0 0
Sao Paulo
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Smolyan
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Plovdiv
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sofia
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Sofiya
Country [44] 0 0
Canada
State/province [44] 0 0
Manitoba
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
Canada
State/province [46] 0 0
Saskatchewan
Country [47] 0 0
Chile
State/province [47] 0 0
Los Lagos
Country [48] 0 0
Chile
State/province [48] 0 0
Region Metropolitana De Santiago
Country [49] 0 0
Chile
State/province [49] 0 0
Region Metropolitana Santiago
Country [50] 0 0
Chile
State/province [50] 0 0
Santiago
Country [51] 0 0
China
State/province [51] 0 0
Anhui
Country [52] 0 0
China
State/province [52] 0 0
Beijing
Country [53] 0 0
China
State/province [53] 0 0
Guangdong
Country [54] 0 0
China
State/province [54] 0 0
Hunan
Country [55] 0 0
China
State/province [55] 0 0
Jiangsu
Country [56] 0 0
China
State/province [56] 0 0
Jiangxi
Country [57] 0 0
China
State/province [57] 0 0
Sichuan
Country [58] 0 0
Colombia
State/province [58] 0 0
Atlantico
Country [59] 0 0
Colombia
State/province [59] 0 0
Cundinamarca
Country [60] 0 0
Colombia
State/province [60] 0 0
Santander
Country [61] 0 0
Colombia
State/province [61] 0 0
Valle Del Cauca
Country [62] 0 0
Croatia
State/province [62] 0 0
Grad Zagreb
Country [63] 0 0
Croatia
State/province [63] 0 0
Istarska Zupanija
Country [64] 0 0
Croatia
State/province [64] 0 0
Krapinske Toplice
Country [65] 0 0
France
State/province [65] 0 0
Haute-Garonne
Country [66] 0 0
France
State/province [66] 0 0
Herault
Country [67] 0 0
France
State/province [67] 0 0
Provence-Alpes-Cote-d Azur
Country [68] 0 0
France
State/province [68] 0 0
Somme
Country [69] 0 0
France
State/province [69] 0 0
Orléans
Country [70] 0 0
France
State/province [70] 0 0
Rouen
Country [71] 0 0
Germany
State/province [71] 0 0
Brandenburg
Country [72] 0 0
Germany
State/province [72] 0 0
Saarland
Country [73] 0 0
Germany
State/province [73] 0 0
Planegg
Country [74] 0 0
Germany
State/province [74] 0 0
Ratingen
Country [75] 0 0
Greece
State/province [75] 0 0
Attiki
Country [76] 0 0
Greece
State/province [76] 0 0
Kriti
Country [77] 0 0
Hungary
State/province [77] 0 0
Veszprem
Country [78] 0 0
Hungary
State/province [78] 0 0
Budapest
Country [79] 0 0
Hungary
State/province [79] 0 0
Szekesfehervar
Country [80] 0 0
Hungary
State/province [80] 0 0
Szolnok
Country [81] 0 0
Italy
State/province [81] 0 0
Ancona
Country [82] 0 0
Italy
State/province [82] 0 0
Firenze
Country [83] 0 0
Italy
State/province [83] 0 0
Milan
Country [84] 0 0
Japan
State/province [84] 0 0
Aichi
Country [85] 0 0
Japan
State/province [85] 0 0
Fukui
Country [86] 0 0
Japan
State/province [86] 0 0
Fukuoka
Country [87] 0 0
Japan
State/province [87] 0 0
Hokkaido
Country [88] 0 0
Japan
State/province [88] 0 0
Hyogo
Country [89] 0 0
Japan
State/province [89] 0 0
Kagawa
Country [90] 0 0
Japan
State/province [90] 0 0
Kochi
Country [91] 0 0
Japan
State/province [91] 0 0
Kumamoto
Country [92] 0 0
Japan
State/province [92] 0 0
Miyazaki
Country [93] 0 0
Japan
State/province [93] 0 0
Nagasaki
Country [94] 0 0
Japan
State/province [94] 0 0
Tokyo
Country [95] 0 0
Japan
State/province [95] 0 0
Yamaguchi
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Chungcheongnamdo
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Daejeon Gwang Yeogsi
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gwangju Gwang Yeogsi
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Seoul Teugbyeolsi
Country [100] 0 0
Mexico
State/province [100] 0 0
Ciudad De Mexico
Country [101] 0 0
Mexico
State/province [101] 0 0
Distrito Federal
Country [102] 0 0
Mexico
State/province [102] 0 0
Jalisco
Country [103] 0 0
Mexico
State/province [103] 0 0
Chihuahua
Country [104] 0 0
Portugal
State/province [104] 0 0
Setubal
Country [105] 0 0
Portugal
State/province [105] 0 0
Viana Do Castelo
Country [106] 0 0
Portugal
State/province [106] 0 0
Lisboa
Country [107] 0 0
Puerto Rico
State/province [107] 0 0
San Juan
Country [108] 0 0
Romania
State/province [108] 0 0
Olt
Country [109] 0 0
Romania
State/province [109] 0 0
Timis
Country [110] 0 0
Romania
State/province [110] 0 0
Bacau
Country [111] 0 0
Serbia
State/province [111] 0 0
Beograd
Country [112] 0 0
Serbia
State/province [112] 0 0
Vojvodina
Country [113] 0 0
South Africa
State/province [113] 0 0
Gauteng
Country [114] 0 0
South Africa
State/province [114] 0 0
Kwazulu-Natal
Country [115] 0 0
South Africa
State/province [115] 0 0
Western Cape
Country [116] 0 0
Spain
State/province [116] 0 0
A Coruna
Country [117] 0 0
Spain
State/province [117] 0 0
Alicante
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Valencia
Country [120] 0 0
United Kingdom
State/province [120] 0 0
London, City Of
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Norfolk
Country [122] 0 0
United Kingdom
State/province [122] 0 0
London
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Portsmouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed.

Upadacitinib is an approved drug for the treatment of RA. This study is double-blinded means that neither the participants nor the study doctors will know who will be given upadacitinib and who will be given adalimumab. Study doctors put the participants in 1 of the 2 groups, called treatment arms randomly, to receive either upadacitinib or adalimumab. There is 1 in 2 chance that participants will receive adalimumab. Each group consists of 2 periods. Approximately 480 participants diagnosed with RA will be enrolled in approximately 250 sites across the world.

Participants will receive the oral upadacitinib once daily and matching adalimumab placebo every other week, or the subcutaneous adalimumab every other week and matching upadacitinib placebo once daily during Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1 and will be followed for 30 days and 70 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Trial website
https://clinicaltrials.gov/study/NCT05814627
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ABBVIE CALL CENTER
Address 0 0
Country 0 0
Phone 0 0
844-663-3742
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05814627